Medtronic recalls MiniMed 770G insulin pumps (MMT-1880-1892) due to potential insulin over- or under-delivery when pump height changes, risking severe hypoglycemia, hyperglycemia, or death.
All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and hydrodynamic pressures. Insulin over-delivery, which can occur when the pump is elevated relative to the infusion site, can result in severe hypoglycemia, altered mental status, seizure, coma, or death. An under-delivery of insulin, which can occur at lowered pump height conditions relative to the infusion site, can result in severe hyperglycemia, dehydration, diabetic ketoacidosis, or death.
Medtronic is recalling specific MiniMed 770G insulin pumps that may deliver too much or too little insulin if moved up or down relative to the body. This can cause life-threatening low blood sugar, high blood sugar, or death.
When the pump is elevated above the infusion site, it can deliver too much insulin, causing severe hypoglycemia (dangerously low blood sugar) that may lead to coma or death. When the pump is lowered below the infusion site, it can deliver too little insulin, causing severe hyperglycemia (dangerously high blood sugar) that may lead to dehydration or diabetic ketoacidosis.
People with diabetes who use the recalled MiniMed 770G insulin pumps are affected. Those who have the pumps with model numbers MMT-1880 through MMT-1892 are most at risk.
Check the pump's model number on the device label. The affected models are MMT-1880, MMT-1881, MMT-1882, MMT-1890, MMT-1891, or MMT-1892. These pumps were sold between 2018 and 2020.
Discontinue use of the affected MiniMed 770G insulin pump to prevent potential insulin over- or under-delivery.
The affected models are MMT-1880, MMT-1881, MMT-1882, MMT-1890, MMT-1891, and MMT-1892.
Elevating the pump above the infusion site can cause severe hypoglycemia (dangerously low blood sugar) leading to coma or death. Lowering the pump below the infusion site can cause severe hyperglycemia (dangerously high blood sugar) leading to dehydration or diabetic ketoacidosis.
The recall does not specify a return process, but you should stop using the pump immediately and contact Medtronic for further instructions.
We’ve drafted a message you can send Medtronic to request your refund or repair — edit it as you like.
Subject: Recall Z-1742-2026 — Medtronic Medtronic Hello, I own a Medtronic that is covered by recall Z-1742-2026 from Medtronic. I’m writing to arrange the remedy described in the recall (a refund, repair, or replacement as applicable). Could you please tell me the next steps to resolve this? Thank you.
Experiences, tips, and questions from readers. Every comment is reviewed before it appears.
No comments yet — be the first to share your experience.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
